You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》摩通重申康方生物(09926.HK)「增持」投资评级 目标价33元
阿思达克 10-13 14:03
摩根大通发表研究报告,指出康方生物(09926.HK)公布了三项令人鼓舞的业务更新,包括与中生制药(01177.HK)共同开发的抗PD-1单抗药物「派安普利」达到了由独立影像评估的客观缓解率(ORR)主要终点;新型肿瘤免疫治疗双特异性抗体新药PD-1/CTLA-4(研发代号:AK104)获得中国国家药品监督管理局药品审评中心(CDE)审核同意,纳入「突破性治疗药物品种」;以及抗PD-1单抗药物派安普利(安尼可)(研发代号:AK105)联合化疗用於一线治疗转移性鳞状非小细胞肺癌的III期注册性临床试验於2020年9月完成入组。

该行相信,公司将继续在研发渠道方面取得稳健进展。凭藉经过验证的基於单克隆抗体的药物开发平台和深入而均衡的药物开发渠道,相信公司在长期增长方面处於有利位置。重申「增持」投资评级,目标价33元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account